R&D Parkinson’s Awareness Month may end, but the research impera... As Parkinson’s Awareness Month comes to a close, the urgency to challenge the status quo has never been greater.
R&D Women in STEM: Balancing the field from the beginning pharmaphorum spoke with three female experts from Thermo Fisher Scientific about women in STEM today and tomorrow.
R&D The devil’s in the details: Navigating complexity & nuance i... Clinical trial expansion comes with complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations.
R&D Innovative direct delivery strategies to unlock oligonucleot... Oligo therapies are emerging as promising therapeutics with the potential to address previously untreatable conditions.
R&D DiaMedica’s novel biologic basal dilator: Bringing hope to p... pharmaphorum spoke with DiaMedica’s CEO, Rick Pauls, about the company's efforts in preeclampsia, early-onset preeclampsia, and ischaemic stroke.
R&D Sponsored 12 Questions with Faruk Uzman Find out more about Faruk Uzman, VP EMEA at Boston Scientific, in a new 12 Questions With.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
